Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 128
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Gynecol Endocrinol ; 36(7): 599-604, 2020 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-32321334

RESUMEN

To verify the different expression of G protein-coupled estrogen receptor 1 (GPER1) among normal uterine, leiomyoma, and adenomyosis tissues. Normal uterine, leiomyoma, and adenomyosis tissue samples were obtained from women aged 35-52 years from a tertiary university hospital. The tissue samples were subjected to immunohistochemical, Western blot, and reverse-transcription polymerase chain reaction (RT-PCR) analyses of GPER1. GPER1 protein expression was confirmed in the tissues by immunohistochemical and Western blot analyses and compared with GPER1 mRNA levels using RT-PCR. GPER1 was detected in the tissue samples of leiomyoma and adenomyosis, which are estrogen-dependent diseases. GPER1 expression was similar between normal uterine and leiomyoma tissues but was reduced in adenomyosis tissue. The level of phosphorylated extracellular signal-regulated kinases 1/2 was lower and higher in leiomyoma and adenomyosis tissues, respectively, than in normal tissue, but the differences among the groups were not statistically significant. Our immunohistochemical, Western blot, and RT-PCR results suggest that GPER1 expression is involved in cell proliferation in leiomyoma and in cell invasion and migration in adenomyosis. Functional studies of GPER1 involving larger sample sizes should be performed to confirm the adenomyosis and leiomyoma disease mechanisms and eventually to develop new therapeutic interventions for these diseases.


Asunto(s)
Adenomiosis/genética , Leiomioma/genética , Miometrio/metabolismo , Receptores de Estrógenos/genética , Receptores Acoplados a Proteínas G/genética , Neoplasias Uterinas/genética , Adenomiosis/metabolismo , Adenomiosis/patología , Adulto , Estudios de Casos y Controles , Femenino , Expresión Génica , Humanos , Inmunohistoquímica , Leiomioma/metabolismo , Leiomioma/patología , Persona de Mediana Edad , Miometrio/patología , Receptores de Estrógenos/metabolismo , Receptores Acoplados a Proteínas G/metabolismo , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Neoplasias Uterinas/metabolismo , Neoplasias Uterinas/patología , Útero/metabolismo , Útero/patología
2.
Arch Gynecol Obstet ; 301(3): 801-807, 2020 03.
Artículo en Inglés | MEDLINE | ID: mdl-31858233

RESUMEN

OBJECTIVE: Mucin family members mucin 1 (MUC1) and mucin 4 (MUC4) play an important role in transformation and adhesion, and are known markers for the detection of cancer. However, the pathophysiology of endometriosis associated with the mucin gene is unclear. In this study, we analyzed the relationship between MUC1 and MUC4 single-nucleotide polymorphisms (SNPs) and the risk for endometriosis. METHODS: We performed a case-controlled study of 29 endometriosis clinical samples and 27 functional cysts as control. Sixteen SNPs (rs145224844, rs139620330, rs144273480, rs1611770, rs146141676, rs201798179, rs201815857, rs199840128, rs200788986, rs141460657, rs183700327, rs199768496, rs191544901, rs200639498, rs148332231, and rs11465209) of MUC1 gene and eight SNPs (rs1104760, rs1106502, rs882605, rs2291651, rs2291652, rs2291653, rs2291654, and rs375068067) of the MUC4 gene were identified. We amplified SNP sites by polymerase chain reaction (PCR) using specific primer sets followed by DNA sequencing. RESULTS: The single mutation analysis of MUC4 showed that MUC4 mutations had no effect on the risk for endometriosis, but the frequencies of haplotypes [T/T + T/T + C/C] (rs2291653, 2291654 and rs375068067) were associated with endometriosis. CONCLUSION: The MUC1 genotype may not be correlated with endometriosis susceptibility. However, MUC4 polymorphisms are associated with the risk for endometriosis in Korean women.


Asunto(s)
Endometriosis/genética , Mucinas/genética , Polimorfismo Genético/genética , Polimorfismo de Nucleótido Simple/genética , Adulto , Estudios de Casos y Controles , Femenino , Humanos , Persona de Mediana Edad , República de Corea
3.
J Bone Miner Metab ; 37(3): 563-572, 2019 May.
Artículo en Inglés | MEDLINE | ID: mdl-30238428

RESUMEN

Patient-reported outcomes (PROs) provide practical guides for treatment; however, studies that have evaluated PROs of women in Korea with postmenopausal osteoporosis (PMO) are lacking. This cross-sectional, multi-center (29 nationwide hospitals) study, performed from March 2013 to July 2014, aimed to assess PROs related to treatment satisfaction, medication adherence, and quality of life (QoL) in Korean PMO women using osteoporosis medication for prevention/treatment. Patient demographics, clinical characteristics, treatment patterns, PROs, and experience using medication were collected. The 14-item Treatment Satisfaction Questionnaire for Medication (TSQM) (score-range, 0-100; domains: effectiveness, side effects, convenience, global satisfaction), Osteoporosis-Specific Morisky Medication Adherence Scale (OS-MMAS) (score-range, 0-8), and EuroQol-5 dimensions questionnaire (index score range, - 0.22 to 1.0; EuroQol visual analog scale score range, 0-100) were used. To investigate factors associated with PROs, linear (treatment satisfaction/QoL) or logistic (medication adherence) regression analyses were conducted. A total of 1804 patients (age, 62 years) were investigated; 60.1% used bisphosphonate, with the majority (67.2%) using weekly medication, 27.8% used daily hormone replacement therapy, and 12.1% used daily selective estrogen receptor modulator. Several patients reported gastrointestinal (GI) events (31.6%) and dental visits due to problems (24.1%) while using medication. Factors associated with the highest OS-MMAS domain scores were convenience and global satisfaction. GI events were associated with non-adherence. TSQM scores for effectiveness, side effects, and GI risk factors were significantly associated with QoL. Our study elaborately assessed the factors associated with PROs of Korean PMO women. Based on our findings, appropriate treatment-related adjustments such as frequency/choice of medications and GI risk management may improve PROs.


Asunto(s)
Cumplimiento de la Medicación , Osteoporosis Posmenopáusica/epidemiología , Medición de Resultados Informados por el Paciente , Satisfacción del Paciente , Calidad de Vida , Conservadores de la Densidad Ósea/uso terapéutico , Estudios Transversales , Difosfonatos/uso terapéutico , Femenino , Humanos , Cumplimiento de la Medicación/estadística & datos numéricos , Persona de Mediana Edad , Osteoporosis Posmenopáusica/tratamiento farmacológico , República de Corea , Encuestas y Cuestionarios , Resultado del Tratamiento
4.
J Obstet Gynaecol ; 37(4): 503-509, 2017 May.
Artículo en Inglés | MEDLINE | ID: mdl-28421904

RESUMEN

This study investigated the effects of 1α, 25-dihydroxyvitamin D3-induced cell death and its underlying molecular mechanisms in Ishikawa endometrial carcinoma cells. The effects of 1α, 25-dihydroxyvitamin D3 on Ishikawa cells were examined by 3-[4,5-dimethylthiazol-2-yl]-2.5-diphenyl-tetrazolium bromide, thiazolyl blue (MTT) assay. 1α, 25-dihydroxyvitamin D3 was shown to induce programmed cell death in Ishikawa endometrial carcinoma cells by activation of caspase-3 and caspase-9, along with elevation of Bcl-2 and Bcl-xL. Cell viability was reduced by 1α, 25-dihydroxyvitamin D3 in a concentration-dependent manner up to 2.5 µM. In addition, ezrin phosphorylation increased with the 1α, 25-dihydroxyvitamin D3 concentration (0-0.5 µM). The protein level of caspase-9 was increased by 1α, 25-dihydroxyvitamin D3 up to 0.5 µM. This is the first report regarding the efficacy and molecular mechanisms underlying the effects of 1α, 25-dihydroxyvitamin D3 in endometrial cancer cells. Our findings indicate that 1α, 25-dihydroxyvitamin D3 induces endometrial cancer cell death in a concentration-dependent manner. Impact statement Up to date, there is no report about the efficacy and molecular underlying mechanisms on the effect of vitamin D3 in endometrial cancer cells. Our findings indicate that 1α, 25-dihydroxyvitamin D3. which is an active metabolite of vitamin D3, induces Ishikawa endometrial cancer cell death in a concentration-dependent manner by activation of caspase-3 and -9, along with elevation of Bcl-2 and Bcl-xL. In addition, the same concentration of 1α, 25-dihydroxyvitamin D3 that provoked apoptotic signals caused phosphorylation of ezrin at threonine 567 in a VDR-dependent manner. This study suggests that 1α, 25-dihydroxyvitamin D3 within the optimal range (0.5 uM) would induce apoptosis through Fas-ezrin-caspase-3, -8, -9 signalling axis which may be a critical cell death regulator in Ishikawa endometrial cancer cell. Further study will be more interesting to address molecular connections or prove this critical optimal concentration range of vitamin D.


Asunto(s)
24,25-Dihidroxivitamina D 3/farmacocinética , Adenocarcinoma/metabolismo , Apoptosis/efectos de los fármacos , Neoplasias Endometriales/metabolismo , Regulación Neoplásica de la Expresión Génica/efectos de los fármacos , Adenocarcinoma/patología , Caspasa 3/metabolismo , Caspasa 9/metabolismo , Células Cultivadas , Proteínas del Citoesqueleto , Neoplasias Endometriales/patología , Femenino , Humanos , Fosforilación
5.
Arch Gynecol Obstet ; 292(2): 377-81, 2015 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-25666480

RESUMEN

OBJECTIVE: The goal of this study was to investigate differential expression of the cell cycle signaling proteins p27 and Jun activation domain-binding protein 1 (Jab1) in benign ovarian cysts of patients with endometriosis compared to controls. METHODS: Ovarian tissues of 26 endometriosis and 28 non-endometriosis patients were used to evaluate expression of p27 and Jab1 by immunohistochemistry. RESULTS: There are no differences in clinical characteristics between the endometriosis and non-endometriosis group. In the endometriosis group, CD10, Jab1 and p27 were positive in 50, 48.3 and 57.7 % of cases, respectively, compared to 14.3, 17.9 and 50 %, respectively, in the non-endometriosis group. Jab1 and p27 were positive in 69.2 and 84.6 %, respectively, of the definite endometriosis cases. CONCLUSIONS: These results demonstrate that Jab1 expression was increased in endometriosis, while p27 expression was similar in the endometriosis and non-endometriosis groups.


Asunto(s)
Inhibidor p27 de las Quinasas Dependientes de la Ciclina/metabolismo , Endometriosis/metabolismo , Péptidos y Proteínas de Señalización Intracelular/metabolismo , Péptido Hidrolasas/metabolismo , Adulto , Complejo del Señalosoma COP9 , Estudios de Casos y Controles , Proteínas de Ciclo Celular/metabolismo , Femenino , Humanos , Inmunohistoquímica , Persona de Mediana Edad , Estadificación de Neoplasias
6.
Int Urogynecol J ; 25(5): 695-7, 2014 May.
Artículo en Inglés | MEDLINE | ID: mdl-24085145

RESUMEN

We report on a patient who underwent total vaginal hysterectomy for urinary incontinence 8 years previously with a sling operation using transobturator tape (TOT). She was admitted to our hospital after complaints of vaginal discharge, foul odor, and bleeding, left thigh pain, and edema. Magnetic resonance imaging (MRI) and computed tomography (CT) revealed a fistula tract from the vagina or urethra with remnant sling tape. We removed the remnant tape using intraoperative ultrasonography. This case exemplifies the rare occurrence of a vaginal fistula extending to the obturator, adductor, and pectineus muscles combined with myositis after TOT placement. It is important that urogynecologists recognize that TOT procedures may result in complications accompanied by common recurrent vaginal symptoms, such as vaginal odor and spotting, which can be identified by MRI or CT.


Asunto(s)
Edema/etiología , Pierna , Cabestrillo Suburetral/efectos adversos , Enfermedades Uretrales/etiología , Fístula Urinaria/etiología , Excreción Vaginal/etiología , Fístula Vaginal/etiología , Enfermedad Crónica , Femenino , Humanos , Persona de Mediana Edad
7.
Nutrients ; 16(6)2024 Mar 13.
Artículo en Inglés | MEDLINE | ID: mdl-38542724

RESUMEN

This study targeted elderly women over 60 years old (109 persons), divided them into an exercise group and a control group, and implemented a 12-week physical activity program for the exercise group. Body composition, muscle, blood tests, depression, quality of life (QoL), nutritional status, and physical strength were compared and analyzed. The physical activity program was organized through a consultative body of experts, was performed for about 60 min each time in the type and order of exercise appropriate for elderly women, and consisted of a combination of exercise using a band, gymnastics, and stretching. Changes in the muscle index and muscle mass before and after the program were selected as the primary efficacy evaluations. In the exercise group, waist circumference significantly decreased, and the muscle index significantly increased compared to the control group. The number of subjects who showed sarcopenia with a muscle index of 5.4 or less in the exercise group significantly decreased from 22 (38.6%) before program implementation to 13 (22.8%). According to the results of secondary effectiveness evaluation, high-density lipoprotein cholesterol and apolipoprotein (Apo) A were significantly increased in the exercise group compared to the control group, and Apo B, triglyceride, and c-reactive protein showed a significant decrease. Regular physical activity is very important for improving the health and QoL of elderly women, and as a result of applying a customized program, effects such as increased muscle index, improvement of sarcopenia, and improvement of blood lipid status were confirmed. Therefore, it is believed that the physical activity program developed through this study can be applied as a community program for elderly women.


Asunto(s)
Sarcopenia , Humanos , Femenino , Anciano , Persona de Mediana Edad , Sarcopenia/prevención & control , Sarcopenia/metabolismo , Calidad de Vida , Fuerza Muscular/fisiología , Ejercicio Físico/fisiología , Estado Nutricional , Composición Corporal/fisiología , Músculo Esquelético/metabolismo
9.
J Menopausal Med ; 29(2): 45-50, 2023 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-37691311

RESUMEN

Women undergo various physical changes because of hormonal changes occurring after menopause. Some representative changes caused by the reduction in estrogen levels in these women are dyslipidemia, abnormal lipoprotein levels, obesity, weight gain, and changes in body fat distribution. A characteristic of women approaching menopause is the shift of fat from their hips and thighs to their abdomen. Notably, fat accumulation is common in internal organs, resulting in male-pattern obesity among women approaching menopause; therefore, these women require more exercise therapy than premenopausal women to prevent and treat obesity. To the best of our knowledge, no effective exercise therapy guidelines have been established for postmenopausal women; therefore, I aimed to suggest more effective diet and exercise therapies for postmenopausal women with obesity. For this purpose, I organized the diet and exercise protocol by collaborating with an obstetrician and a researcher specializing in sports medicine; further, this protocol was actually applied to all participants. The results indicated that the protocol is effective in reducing weight; however, joint pain was commonly noted in participants who dropped out of the program. Based on the evaluation of joint pain, this study found that it is necessary to perform exercise therapy by avoiding weight-bearing activities and reinforcing personalized joint strengthening exercises because reduced estrogen level is an important factor exacerbating arthritis in postmenopausal women.

10.
Arch Med Sci ; 19(2): 488-498, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-37034541

RESUMEN

Introduction: Docosahexaenoic acid (DHA) supplementation has been reported to negatively correlate with cancer cell proliferation and tumour development in many cancer types. Although cumulative evidence has demonstrated the apoptotic effect and cytotoxicity of DHA against tumour development in many cell types, the precise cellular and biochemical mechanisms of DHA-induced apoptosis in human endometrial cancer cells have not been investigated. Material and methods: MTT assay was performed to confirm the degree of apoptosis by combining treatment with DHA and triacsin C in endometrial cancer cell line. The synergistic effects of triacsin C and DHA were identified by performing flowcytometry and immunoblotting analysis. Results: Combined treatment with DHA and triacsin C significantly induced apoptosis in RL95-2 endometrial carcinoma cells. Combined treatment with 125 µM DHA and 5 µM triacsin C significantly increased the sub-G1 population and apoptotic fragments in endometrial carcinoma cells. It was also demonstrated that DHA and triacsin C induced apoptosis through mitochondrial pathways via caspases-9, -3, and -7 as well as through the extrinsic pathway by activation of caspase-8/BID. Conclusions: Further elucidation of the apoptotic mechanisms involving DHA treatment with ACS ablation could shed light on possible new treatment strategies for endometrial cancer. In addition, further research into the mechanisms of DHA and triacsin C-induced apoptotic mechanisms may lead to the development of therapeutic strategies for endometrial cancer.

12.
Ulus Travma Acil Cerrahi Derg ; 18(3): 274-6, 2012 May.
Artículo en Inglés | MEDLINE | ID: mdl-22864724

RESUMEN

Operating room fires occur very rarely. Nevertheless, a disaster can complicate almost any kind of surgery. The majority of operating room fires result from the use of alcohol- based surgical preparation solutions, electro-surgical equipment, or flammable drapes in an oxygen-rich environment. We report a patient with an ovarian cyst and uterine myomas who suffered a flame burn while undergoing gynecological surgery.


Asunto(s)
Quemaduras/etiología , Incendios , Leiomioma/cirugía , Quirófanos , Quistes Ováricos/cirugía , Neoplasias Uterinas/cirugía , Antiinfecciosos Locales , Quemaduras/terapia , Electrocirugia/efectos adversos , Electrocirugia/instrumentación , Etanol , Femenino , Incendios/prevención & control , Hematoma/complicaciones , Hematoma/cirugía , Humanos , Laparoscopía , Leiomioma/complicaciones , Persona de Mediana Edad , Quistes Ováricos/complicaciones , Enfermedades del Ovario/complicaciones , Enfermedades del Ovario/cirugía , Neoplasias Uterinas/complicaciones
13.
Reprod Biol Endocrinol ; 9: 28, 2011 Mar 02.
Artículo en Inglés | MEDLINE | ID: mdl-21362202

RESUMEN

Human endometrium resists embryo implantation except during the 'window of receptivity'. A change in endometrial gene expression is required for the development of receptivity. Uterine calbindin-D28k (CaBP-28k) is involved in the regulation of endometrial receptivity by intracellular Ca2+. Currently, this protein is known to be mainly expressed in brain, kidneys, and pancreas, but potential role(s) of CaBP-28k in the human uterus during the menstrual cycle remain to be clarified. Thus, in this study we demonstrated the expression of CaBP-28k in the human endometrium in distinct menstrual phases. During the human menstrual cycle, uterine expression levels of CaBP-28k mRNA and protein increased in the proliferative phase and fluctuated in these tissues, compared with that observed in other phases. We assessed the effects of two sex-steroid hormones, 17beta-estradiol (E2) and progesterone (P4), on the expression of CaBP-28k in Ishikawa cells. A significant increase in the expression of CaBP-28k mRNA was observed at the concentrations of E2 (10(-9 to -7) M). In addition, spatial expression of CaBP-28k protein was detected by immunohistochemistry. CaBP-28k was abundantly localized in the cytoplasm of the luminal and glandular epithelial cells during the proliferative phases (early-, mid-, late-) and early-secretory phase of menstrual cycle. Taken together, these results indicate that CaBP-28k, a uterine calcium binding protein, is abundantly expressed in the human endometrium, suggesting that uterine expression of CaBP-28k may be involved in reproductive function during the human menstrual cycle.


Asunto(s)
Estradiol/farmacología , Regulación de la Expresión Génica , Ciclo Menstrual/fisiología , Proteína G de Unión al Calcio S100/biosíntesis , Adulto , Calbindina 1 , Calbindinas , Endometrio/metabolismo , Estrógenos/farmacología , Femenino , Humanos , Ciclo Menstrual/efectos de los fármacos , Persona de Mediana Edad , Progesterona/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA